So many drugs, so little time: The future challenge of cystic fibrosis care

Chest

Volumn 123, Issue 1, 2003, Pages 3-5

  Boyle, Michael P ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; COLISTIN; DEOXYRIBONUCLEASE; MUCOLYTIC AGENT; PANCREAS ENZYME; SODIUM CHLORIDE; TOBRAMYCIN;

AEROSOL; CLINICAL RESEARCH; CYSTIC FIBROSIS; DEVICE; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; EXERCISE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERMETHOD COMPARISON; LUNG CLEARANCE; LUNG FUNCTION; MEDICAL NEBULIZER; METERED DOSE INHALER; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0037245866     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.1.3     Document Type: Editorial

References (7)

1. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245:1073-1080
2. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23:5-27
3. Cystic Fibrosis Foundation. Patient registry 2000: annual report. Bethesda, MD: Cystic Fibrosis Foundation, 2001
4. Kettler LJ, Sawyer SM, Winefield HR, et al. Determinants of adherence in adults with cystic fibrosis. Thorax 2002; 57:459-464
5. Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest 2001; 120(suppl):89S-93S
6. Dolovich M. New propellant-free technologies under investigation. J Aerosol Med 1999; 12(suppl):S9-S17
7. Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med 1999; 12(suppl):S19-S24